• Molecular NameBendamustine
  • SynonymNA
  • Weight358.269
  • Drugbank_IDN/A
  • ACS_NO16506-27-7
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.04
  • pkaN/A
  • LogD (pH=7, predicted)0.81
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.0
  • LogSw (predicted, AB/LogsW2.0)0.37
  • Sw (mg/ml) (predicted, ACD/Labs)0.24
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds9
  • TPSA58.36
  • StatusN/A
  • AdministrationIntravenous infusion
  • PharmacologyA nitrogen mustard used in the treatment of chronic lymphocytic leukemia (CLL)[1] and non-Hodgkin's lymphoma (NHL). It belongs to the family of drugs called alkylating agents. It is also being studied for the treatment of sarcoma.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding95.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHydrolyzed to inactive metabolites. Two minor metabolites (M3 and M4) formed by CYP1A2
  • Half life40 min (bendamustine), 3 h (M3), 30 min (M4)
  • ExcretionMostly fecal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A